Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/10926
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMendonça, Débora Vasconcelos Costa-
dc.contributor.authorMartins, Vivian Tamietti-
dc.contributor.authorLage, Daniela Pagliara-
dc.contributor.authorRibeiro, Patrícia Aparecida Fernandes-
dc.contributor.authorCarvalho, Ana Maria Ravena Severino-
dc.contributor.authorDias, Anna Letícia T.-
dc.contributor.authorMiyazaki, Carolina Kei-
dc.contributor.authorSouza, Daniel Menezes-
dc.contributor.authorRoatt, Bruno Mendes-
dc.contributor.authorTavares, Carlos Alberto Pereira-
dc.contributor.authorDuarte, Mariana Costa-
dc.contributor.authorCoelho, Eduardo Antônio Ferraz-
dc.date.accessioned2019-04-03T16:37:22Z-
dc.date.available2019-04-03T16:37:22Z-
dc.date.issued2018-
dc.identifier.citationMENDONÇA, D. V. C. et al. Comparing the therapeutic efficacy of different amphotericin Bcarrying delivery systems against visceral leishmaniasis. Experimental Parasitology, v. 186, p. 24-35, mar. 2018. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0014489417303077?via%3Dihub>. Acesso em: 22 fev. 2019.pt_BR
dc.identifier.issn00144894-
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/10926-
dc.description.abstractAmphotericin B (Amp) has been well-successfully used to treat against Leishmania infection, although high toxicity has been found in patients. In the present study, Amp was administered in Leishmania infantum-infected BALB/c mice by three distinct delivery systems aiming to compare their efficacy against challenge infection, as well as their side effects in a murine visceral leishmaniasis (VL) model. This product was administered in a Poloxamer P407 (Pluronic® F127)-based polymeric micelle system (Amp/M), in the Ambisome® formulation (Lip-Amp) or in a free format (free Amp). Glucantime® (Gluc) was used as a comparative drug. Aiming to evaluate different endpoints of the treatments, the efficacy of the compounds was investigated one and 15-days after the therapeutic regimens, determining the parasite load by a limiting dilution assay and a quantitative PCR (qPCR) technique, as well as evaluating the immune response generated in the infected and treated animals. In the results, Amp/M or Lip-Amp-treated mice presented the best outcomes, since significant parasite load reductions were found in the evaluated organs, as well as a parasite-specific Th1 immune response was observed in the animals. In addition, no hepatic or renal damage was found in these mice. On the other hand, free Amp or Gluc induced toxicity in the animals, which was associated with a low Th1 immune response. Comparatively, Amp/M was the most effective drug in our experimental model, and results showed that the Amp-carrying system could be considered as a future alternative in studies against VL.pt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectPoloxamer 407pt_BR
dc.subjectTreatmentpt_BR
dc.subjectToxicitypt_BR
dc.titleComparing the therapeutic efficacy of different amphotericin Bcarrying delivery systems against visceral leishmaniasis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
dc.identifier.uri2https://www.sciencedirect.com/science/article/pii/S0014489417303077pt_BR
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_ComparingTherapeuticEfficacy.pdf2,21 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.